Sugammadex, a modified gamma cyclodextrin, was first evaluated in humans in 2006 for the reversal of neuromuscular blockade (NMB) induced by aminosteroidal neuromuscular blocking agents (NMBAs) such as Rocuronium and Vecuronium (1). Unlike neostigmine, an acetylcholinesterase inhibitor that ...
8 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Young Girl Presented with Irritability and Abnormal Behavior
2256 Reached10 Comments4 Likes
Stent Thrombosis After Drug Eluting Stent Implantation
12646 Reached8 Comments8 Likes
Management of Infantile Myoclonic Seizures
1169 Reached3 Comments3 Likes
Unconscious Male in ED following Loss of Motorcycle Control
828 Reached2 Comments2 Likes